Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTA: Standard vs Prolonged DAPT After XINSORB Bioresorbable Scaffold
ChiCTR2000035260Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin in coronary arteriosclerosis (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Major adverse cardiac events (MACE) and BARC type 3 to 5 bleeding events. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2000035260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035260.